

# Balancing between sepsis, AKI and gentamicin in the emergency department

Citation for published version (APA):

Cobussen, M. (2021). *Balancing between sepsis, AKI and gentamicin in the emergency department*. [Doctoral Thesis, Maastricht University]. Maastricht University. <https://doi.org/10.26481/dis.20210527mc>

## Document status and date:

Published: 01/01/2021

## DOI:

[10.26481/dis.20210527mc](https://doi.org/10.26481/dis.20210527mc)

## Document Version:

Publisher's PDF, also known as Version of record

## Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

## General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

## Take down policy

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

# Chapter 8

## Impact for society

## Impact for society

Aminoglycosides, such as gentamicin, are antibiotic drugs that are considered harmful to the kidneys when not used properly. Therefore, there is frequent hesitation in administering these drugs in severely ill patients with sepsis despite there being an indication. However, in a world with increasing antibiotic resistance it is important to keep all antibiotic options open since the options for appropriate empirical antibiotic therapy with the commonly used broad spectrum antibiotics are becoming fewer. Since aminoglycosides kill bacteria rapidly and there is a low resistance rate, it is important to establish the safety and to optimise the use of these agents as the role of aminoglycosides in the treatment of sepsis will possibly increase in the future era with increasing antibiotic resistance.

Previously, the toxicity of aminoglycosides on the kidneys was mostly studied in ICU patients. However, patients often present themselves with sepsis in the emergency department (ED) and the patients in the ED are often less severely ill.

It is likely that the results of ICU studies cannot be extrapolated to ED patients, because the spectrum of sepsis as seen in these patients in the ED differs.

Our studies were the first to evaluate the effect of a single dose of gentamicin in patients with sepsis in the ED. In two different studies, we established that it is safe to administer a single dose of gentamicin to patients with sepsis in the ED with regard to renal function.

Subsequently, we showed that underdosing of gentamicin is a common finding in the ED. In addition, even when the aimed dose of gentamicin is administered, we measured insufficient gentamicin blood levels in a large number of patients, which consequently could lead to potential treatment failure and eventually to worse outcome. After these findings, simulations were executed to determine which dose would be needed to reach adequate gentamicin blood levels. Using the results of these simulations, a new dosing regimen for gentamicin was introduced by the Antibiotic Committee of the Maastricht University Medical Center+. The dose of gentamicin was increased from 5 mg/kg to 7 mg/kg body weight. After the implementation of this new

dosing regimen, gentamicin blood levels were measured again and we found that a gentamicin dose of 7 mg/kg turned out to be sufficient in the majority of patients.

We established that a single dose of gentamicin is safe with regard to renal function. In addition, we showed ways to optimise the use of gentamicin in the ED, which other hospitals and physicians can use to optimise their own antibiotic treatment protocols. Since sepsis is a life-threatening condition and the incidence of sepsis is increasing over the years, adequate antibiotic treatment is of the utmost importance. The findings of our studies are useful for all physicians of all specialties treating patients with sepsis and can help to make a well-informed choice on appropriate and adequate antibiotic therapy in patients with sepsis.

Due to the possible serious side effects of aminoglycosides, since 2018 the Dutch Health and Youth Care Inspectorate (IGJ) demands that informed consent should be obtained when aminoglycosides are administered. However, we showed that a single dose of gentamicin is safe with regard to renal function. Therefore, maybe such a strict disposition is not necessary for only one dose.

The findings of our studies were published in peer-reviewed journals and if possible as an open access manuscript to make them freely accessible via the internet for a broad public, including developing countries. The general public can benefit from the results of our studies due to more appropriate and adequate antibiotic therapy in terms of antibiotic coverage, in a time with worldwide increasing antibiotic resistance.